top of page

Biopharma Daily Stock Updates - 10/29/21

  • Writer: BPIQ
    BPIQ
  • Oct 29, 2021
  • 1 min read

$XBI $124.81 -1%

Covid Updates

$PFE & $BNTX Pfizer and BioNTech Receive First U.S. FDA Emergency Use Authorization of a COVID-19 Vaccine in Children Ages 5 Through 11 Years. source


$ORMP Oramed Announces Oravax's Oral COVID-19 Vaccine Has Received South African Approval to Initiate Phase 1 Trial. source


$NVAX Novavax Files for Provisional Approval of its COVID-19 Vaccine in Australia. source



Pipeline Updates

$ARDX Ardelyx Announces Four Tenapanor Presentations at ASN's Kidney Week 2021. source


$ADCT ADC Therapeutics Announces Validation of its Marketing Authorization Application by the European Medicines Agency for ZYNLONTA®. source


$TALS Talaris Therapeutics Announces Initiation of Phase 2 Clinical Trial of FCR001 in Delayed Tolerance Induction. source



Financial & Business Updates

$BBIO BridgeBio Pharma Announces Collaborations with Columbia University and Mount Sinai to Develop Potential Therapies for Genetic Diseases and Cancers. source


$VALN Valneva Announces the Pricing of its Global Offering of American Depositary Shares and Ordinary Shares. source


$TRIL Trillium Therapeutics Receives Final Court Order Approving Arrangement. source


Posted by FS/DV

 
 
 

Comments

bottom of page